Estudio RAINBOW:
SLP
9
10
Group 4/2 → 2/1
y
6
7
8
Group 2/1
Controls
vival probabilit
3
4
5
ession-free sur
SLP 4/2
Æ
2/1
30m
SLP 2/1
10,4m
SLP 4/2
9,7m
1
2
0
Progr
4/2 → 2/1
205
148
76
41
23
8
3
1
0
0
0
2/1
39
12
2
0
0
0
0
0
0
0
0
1
2
3
4
5
6
7
8
9
10
0
Number at risk*
Follow-up time (years)
*3 patients in the 4/2
Æ
2/1 group and 2 patients in the 2/1 group were not evaluable for PFS
Controls
211
81
20
9
3
2
1
0
0
0
0
Bracarda S et al, Ann Oncol. 2015
